Myocardial infarction: a single-dose drug to support heart repair

By Elodie Vaz | Published on March 17, 2026 | 3 min read


Myocardial infarction is one of the leading causes of cardiovascular mortality and disability worldwide. Even when patients survive the acute event, the consequences for the heart can be long-lasting. The blockage of a coronary artery deprives tissue of oxygen, leading to the death of part of the heart muscle. In the weeks that follow, the heart attempts to repair itself, but this healing phase often results in the formation of fibrotic tissue, which is less functional than healthy cardiac muscle.

This progressive remodeling weakens the organ and can ultimately lead to heart failure. Current treatments mainly aim to limit immediate damage or stabilize cardiac function, but they do not fully prevent this gradual decline. In this context, a strategy designed to support the heart’s natural repair mechanisms could transform post-infarction care.

Objective: enhancing the heart’s natural defenses

In a study published on March 5, 2026, in the journal Science, an international team including researchers from Texas A&M University, Columbia University, and the University of Oxford proposes an innovative approach: stimulating the body’s own production of a cardioprotective hormone.

During a myocardial infarction, the body naturally releases atrial natriuretic peptide (ANP), a hormone capable of reducing cardiac stress and limiting long-term damage. However, this production remains too low to significantly influence recovery.

The researchers’ goal is therefore to temporarily increase ANP production in order to support the heart during the critical healing phase. “The idea is to help the heart draw on its own healing mechanisms,” explained Dr. Ke Huang, assistant professor at the Irma Lerma Rangel College of Pharmacy at Texas A&M and co-author of the study, in a press release. “We are trying to offer patients a treatment that works in harmony with the body, rather than against it. The idea that a single injection could provide support for weeks is very promising.”

A methodology based on self-amplifying RNA

To achieve this, the team developed an intramuscular injection using so-called self-amplifying RNA (saRNA) technology. This approach is inspired by messenger RNA platforms used in some modern vaccines, but with a key difference: the instructions delivered to cells can temporarily replicate themselves.

In practice, the injection provides muscle cells with transient genetic instructions prompting them to produce ANP. Thanks to the self-amplification mechanism, these instructions generate multiple copies of themselves over a short period, prolonging hormone production without requiring high doses.

“This technology gives us a more efficient way to help the body produce what it needs, when it needs it,” said Dr. Huang. “A single dose can produce a sustained effect, something we simply could not achieve with previous methods.”

Encouraging results for cardiac repair

According to the study’s findings, a single injection stimulated ANP production for several weeks. The hormone then circulates in the bloodstream to the heart, where it helps reduce cardiac workload and supports the repair of damaged tissue.

“This is essentially a reinforcement of the heart’s natural defense system,” the researcher explained. “The body already uses ANP as a protective tool. We are simply helping it produce enough for it to be effective during a critical healing period.”

The goal of this prolonged stimulation is to limit harmful scar formation, preserve viable heart muscle, and improve cardiac function after infarction. The researchers hope this will reduce the risk of long-term cardiovascular complications.

This strategy builds on the team’s previous work. In an earlier study, they developed a microneedle patch applied directly to the heart’s surface to deliver reparative hormones. “Our previous research with this patch identified the NPR1 signaling pathway as one of the key drivers of beneficial immunomodulatory effects in cardiac repair,” Dr. Huang noted. “Since ANP is the natural ligand of the NPR1 receptor, this current study extends that work by exploring how ANP-triggered activation leads to cardiac repair.”

The shift from a surgical intervention to a simple injection represents a major advance in terms of clinical feasibility.

Toward a new therapeutic strategy?

This approach aims to intervene during the period when the heart is most vulnerable after an infarction. “Our goal is to protect the heart when it is most vulnerable,” he said. “If we can reduce this initial stress and promote repair, we may be able to alter the course of patient recovery.”

Before any clinical application, further research will be needed to assess safety, optimal timing of administration, and dosing, followed by clinical trials.

However, the simplicity of a single injection could be a major advantage. “It is easy to envision such a treatment being administered quickly and safely,” the professor concluded. “This accessibility is what makes this work so promising. If future studies continue to show similarly strong results, this could become a valuable new tool in the management of heart attacks.”

In the longer term, this strategy could pave the way for a new generation of therapies based on the transient activation of the body’s natural repair mechanisms.  

Read next: Myocardial infarction: rising in-hospital mortality, particularly among women

About the Author – Elodie Vaz
Health journalist, CFPJ graduate (2023).
Élodie explores the marks diseases leave on bodies and, more broadly, on human life. A registered nurse since 2010, she spent twelve years at patients’ bedsides before exchanging her stethoscope for a notebook. She now investigates the links between environment and health, convinced that the vitality of life cannot be reduced to that of humans alone.